Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Slides:

Advertisements

Similar presentations

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.

Advertisements

An alcoholic patient with recurrent renal failure and proteinuria T. Kumagai, Y. Hori, G. Seki, Toshiro Fujita Kidney International Volume 70, Issue 8,

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Beta blockers in the management of chronic kidney disease

Volume 69, Issue 5, Pages (March 2006)

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

Linear and logistic regression analysis

S.J. Nessim, S.V. Jassal, S.V. Fung, C.T. Chan Kidney International

Anemia management in chronic kidney disease

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Reassessment of the care of the patient with chronic kidney disease

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 71, Issue 8, Pages (April 2007)

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 71, Issue 1, Pages (January 2007)

Volume 70, Pages S21-S25 (December 2006)

How to interpret the eGFR in patients with small body surface area

Anemia as a risk factor for chronic kidney disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

S.J. Nessim, S.V. Jassal, S.V. Fung, C.T. Chan Kidney International

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

H. Wong, K. Mylrea, J. Feber, A. Drukker, G. Filler

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.

Blood pressure targets in hemodialysis patients

Volume 70, Issue 7, Pages (October 2006)

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

Recent experience with high-dose intravenous iron administration

Volume 76, Issue 6, Pages (September 2009)

The third World Kidney Day: Looking back and thinking forward

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

J.M. van den Akker, J.F.M. Wetzels, A.J. Hoitsma Kidney International

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

The global challenge of chronic kidney disease

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Volume 71, Issue 4, Pages (February 2007)

The valuable contribution of observational studies to nephrology

Phosphate binders on iron basis: A new perspective?

Organ transplantation goes to the movies

Low triiodothyronine and survival in end-stage renal disease

Volume 72, Issue 2, Pages (July 2007)

Volume 72, Issue 8, Pages (October 2007)

Is it the low-protein diet or simply the salt restriction?

Volume 70, Issue 7, Pages (October 2006)

Is complement a target for therapy in renal disease?

Urinalysis in Western culture: A brief history

Volume 70, Issue 3, Pages (August 2006)

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Volume 70, Issue 6, Pages (September 2006)

Volume 70, Issue 5, Pages (September 2006)

Volume 72, Issue 11, Pages (December 2007)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 69, Issue 8, Pages (April 2006)

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Volume 72, Issue 12, (December 2007)

Volume 71, Issue 3, Pages (February 2007)

Presentation transcript:

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese Kidney International Volume 70, Issue 12, Pages 2116-2123 (December 2006) DOI: 10.1038/sj.ki.5001854 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 This slide shows the percent reduction of proteinuria from baseline in patients treated with spironolactone (25mg/day) in addition to conventional therapy divided on the basis of their eGFR (< or >60ml/min/1.73m2). *P<0.001 vs basal proteinuria; #P<0.05 vs patients with eGFR <60ml/min; @P<0.01 vs patients with eGFR <60ml/min. Kidney International 2006 70, 2116-2123DOI: (10.1038/sj.ki.5001854) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 This slide shows the percent decline in eGFR in patients treated with spironolactone and those treated with conventional therapy. Patients were followed for 1 year. *P<0.001 vs basal eGFR, **P<0.0001 vs basal eGFR. Kidney International 2006 70, 2116-2123DOI: (10.1038/sj.ki.5001854) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 This slide shows the regression line between baseline plasma aldosterone levels and proteinuria in the 165 patients included in the study (r=0.766, P<0.0001). Kidney International 2006 70, 2116-2123DOI: (10.1038/sj.ki.5001854) Copyright © 2006 International Society of Nephrology Terms and Conditions